Patents by Inventor Caroline Rozan

Caroline Rozan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds binding human CD160 and uses thereof
    Patent number: 10975159
    Abstract: Novel compounds which bind specifically to human CD160, including a light chain variable domain (VL), a chosen sequence defined by SEQ ID No: 14 or SEQ ID No: 13 and a heavy chain variable domain (VH), a sequence chosen from SEQ ID No: 11, SEQ ID No: 25, SEQ ID No: 26, SEQ ID No: 27, SEQ ID No: 28, SEQ ID No: 29 or SEQ ID No: 30, fragments thereof or derivatives thereof.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 13, 2021
    Assignee: ELSALYS BIOTECH
    Inventors: Alexandre Calcei, Hélène Haegel, Thierry Menguy, Caroline Rozan
  • COMPOUNDS BINDING HUMAN CD160 AND USES THEREOF
    Publication number: 20200109211
    Abstract: Novel compounds which bind specifically to human CD160, including a light chain variable domain (VL), a chosen sequence defined by SEQ ID No: 14 or SEQ ID No: 13 and a heavy chain variable domain (VH), a sequence chosen from SEQ ID No: 11, SEQ ID No: 25, SEQ ID No: 26, SEQ ID No: 27, SEQ ID No: 28, SEQ ID No: 29 or SEQ ID No: 30, fragments thereof or derivatives thereof.
    Type: Application
    Filed: January 8, 2018
    Publication date: April 9, 2020
    Applicant: ELSALYS BIOTECH
    Inventors: Alexandre CALCEI, Hélène HAEGEL, Thierry MENGUY, Caroline ROZAN
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 10167345
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: January 1, 2019
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS
    Publication number: 20170152324
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of:—a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and,—a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Application
    Filed: February 1, 2017
    Publication date: June 1, 2017
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE
    Inventors: Daniel BATY, Patrick CHAMES, Martine MANSAIS, Brigitte KERFELEC, Caroline ROZAN
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 9598499
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 21, 2017
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS
    Publication number: 20140037631
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Application
    Filed: December 29, 2011
    Publication date: February 6, 2014
    Applicant: UNIVERSITE D'AIX-MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan